3D Tissue Models
12th International Lung Cancer Congress
Park Hyatt Aviara
7100 Four Seasons Point
Carlsbad, California 92011

     *  Abstract Deadline:
       2nd June 2011


   David Gandara,
   Roy Herbst

   Overview and Purpose
   The 12th International Lung Cancer Congress is designed to provide
   participants with an update on advances in lung cancer research and
   therapy, including biology, pathology, screening, staging,
   personalized therapy, maintenance therapy, novel agents, and ongoing
   research in Cooperative Groups. Bringing key data from international
   oncology conferences to participants, the congress will emphasize the
   importance of personalized therapy and address other current topics of
   interest. State-of-the-art treatment for early-stage locally advanced
   and metastatic lung cancer will be discussed. In addition to
   non–small-cell lung cancer ( NSCLC ), the congress will address
   therapy for small-cell lung cancer ( SCLC ) and mesothelioma. A
   regular feature of the International Lung Cancer Congress is an update
   of research efforts from major Cooperative Groups from the United
   States, Europe, and Asia. The format of the meeting will include
   didactic lectures from internationally renowned leaders, debates and
   discussions on controversial topics, extensive panel discussions with
   case scenarios, multidisciplinary tumor boards, question-and-answer
   sessions, and afternoon translational workshops focusing on future
   strategies in development for the treatment of lung cancer.

   Target Audience This educational activity is directed toward medical,
   surgical, and radiation oncologists interested in the treatment of
   patients with lung cancer. Fellows, nurse practitioners, nurses,
   physician assistants, pharmacists, researchers, and other health care
   professionals interested in the treatment of lung cancer are also
   invited to attend. Learning Objectives At the conclusion of this
   congress, you should be able to: • Evaluate the role of CT screening
   for early detection of lung cancer • Discuss the role of
   pulmonologists in the diagnosis of and treatment selection for
   patients with lung cancer • Appraise clinical data on adjuvant
   chemotherapy in patients with early-stage NSCLC • Evaluate the
   efficacy and toxicity of combined modality regimens in locally
   advanced NSCLC • Optimize therapy for patients with metastatic NSCLC
   based on biomarker status and tumor characteristics • Discuss the
   clinical benefits of maintenance therapy in advanced NSCLC •
   Personalize therapeutic approaches for patients with mesothelioma •
   Describe current approaches to patients with limited- and
   extensive-disease SCLC • Discuss clinical data on new targeted agents
   in development for lung cancer • Summarize current research activity
   in lung cancer from national and regional Cooperative Groups Topics
   include: • Computed tomography screening for early detection of lung
   cancer • State-of-the-art treatment of NSCLC by stage • Personalized
   medicine based on tumor and patient characteristics • Current
   approaches to SCLC and mesothelioma • Update on national and
   international Cooperative Group activity in lung cancer • Workshop on
   next-generation targeted agents in lung cancer • Multidisciplinary
   tumor boards

   7100 Four Seasons Point, Carlsbad, CA , 92011, United States

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Thursday, July 21, 2011
Friday, July 22, 2011
Saturday, July 23, 2011
Sunday, July 24, 2011
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.